JP2019081792A5 - - Google Patents

Download PDF

Info

Publication number
JP2019081792A5
JP2019081792A5 JP2019034250A JP2019034250A JP2019081792A5 JP 2019081792 A5 JP2019081792 A5 JP 2019081792A5 JP 2019034250 A JP2019034250 A JP 2019034250A JP 2019034250 A JP2019034250 A JP 2019034250A JP 2019081792 A5 JP2019081792 A5 JP 2019081792A5
Authority
JP
Japan
Prior art keywords
composition
acetate
cellulose
hydroxypropylmethylcellulose
polyvinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019034250A
Other languages
English (en)
Japanese (ja)
Other versions
JP6898960B2 (ja
JP2019081792A (ja
Filing date
Publication date
Priority claimed from JP2017103957A external-priority patent/JP2017141302A/ja
Application filed filed Critical
Publication of JP2019081792A publication Critical patent/JP2019081792A/ja
Publication of JP2019081792A5 publication Critical patent/JP2019081792A5/ja
Priority to JP2021097676A priority Critical patent/JP2021178820A/ja
Application granted granted Critical
Publication of JP6898960B2 publication Critical patent/JP6898960B2/ja
Priority to JP2022177278A priority patent/JP7404485B2/ja
Priority to JP2023209972A priority patent/JP2024019526A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019034250A 2012-03-23 2019-02-27 脳癌の治療 Active JP6898960B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021097676A JP2021178820A (ja) 2012-03-23 2021-06-11 脳癌の治療
JP2022177278A JP7404485B2 (ja) 2012-03-23 2022-11-04 脳癌の治療
JP2023209972A JP2024019526A (ja) 2012-03-23 2023-12-13 脳癌の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
US61/615,082 2012-03-23
JP2017103957A JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017103957A Division JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021097676A Division JP2021178820A (ja) 2012-03-23 2021-06-11 脳癌の治療

Publications (3)

Publication Number Publication Date
JP2019081792A JP2019081792A (ja) 2019-05-30
JP2019081792A5 true JP2019081792A5 (cg-RX-API-DMAC7.html) 2019-12-12
JP6898960B2 JP6898960B2 (ja) 2021-07-07

Family

ID=48048296

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015501952A Pending JP2015514075A (ja) 2012-03-23 2013-03-25 脳癌の治療
JP2017103957A Pending JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療
JP2019034250A Active JP6898960B2 (ja) 2012-03-23 2019-02-27 脳癌の治療
JP2021097676A Pending JP2021178820A (ja) 2012-03-23 2021-06-11 脳癌の治療
JP2022177278A Active JP7404485B2 (ja) 2012-03-23 2022-11-04 脳癌の治療
JP2023209972A Pending JP2024019526A (ja) 2012-03-23 2023-12-13 脳癌の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015501952A Pending JP2015514075A (ja) 2012-03-23 2013-03-25 脳癌の治療
JP2017103957A Pending JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021097676A Pending JP2021178820A (ja) 2012-03-23 2021-06-11 脳癌の治療
JP2022177278A Active JP7404485B2 (ja) 2012-03-23 2022-11-04 脳癌の治療
JP2023209972A Pending JP2024019526A (ja) 2012-03-23 2023-12-13 脳癌の治療

Country Status (30)

Country Link
US (3) US20150110780A1 (cg-RX-API-DMAC7.html)
EP (4) EP3400943B1 (cg-RX-API-DMAC7.html)
JP (6) JP2015514075A (cg-RX-API-DMAC7.html)
KR (3) KR102160462B1 (cg-RX-API-DMAC7.html)
CN (2) CN109223791A (cg-RX-API-DMAC7.html)
AU (4) AU2013234921A1 (cg-RX-API-DMAC7.html)
CA (1) CA2867723C (cg-RX-API-DMAC7.html)
CL (1) CL2014002497A1 (cg-RX-API-DMAC7.html)
CO (1) CO7071139A2 (cg-RX-API-DMAC7.html)
CY (2) CY1120204T1 (cg-RX-API-DMAC7.html)
DK (2) DK2827900T3 (cg-RX-API-DMAC7.html)
ES (2) ES2673165T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180659T1 (cg-RX-API-DMAC7.html)
HU (2) HUE053156T2 (cg-RX-API-DMAC7.html)
IL (3) IL234627B (cg-RX-API-DMAC7.html)
LT (1) LT2827900T (cg-RX-API-DMAC7.html)
MX (1) MX354024B (cg-RX-API-DMAC7.html)
MY (2) MY174883A (cg-RX-API-DMAC7.html)
NZ (4) NZ724544A (cg-RX-API-DMAC7.html)
PH (2) PH12021550360A1 (cg-RX-API-DMAC7.html)
PL (2) PL2827900T3 (cg-RX-API-DMAC7.html)
PT (2) PT2827900T (cg-RX-API-DMAC7.html)
RS (1) RS57140B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018138976A (cg-RX-API-DMAC7.html)
SG (1) SG11201405954YA (cg-RX-API-DMAC7.html)
SI (2) SI2827900T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800251T1 (cg-RX-API-DMAC7.html)
TR (1) TR201808450T4 (cg-RX-API-DMAC7.html)
UA (1) UA122044C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013142875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
US20250387380A1 (en) * 2019-12-30 2025-12-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆(科克)有限公司 癌症治疗方法
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) * 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga

Similar Documents

Publication Publication Date Title
JP6591536B2 (ja) 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物
JP2023509629A5 (cg-RX-API-DMAC7.html)
ES2693686T3 (es) Formulaciones de comprimidos de liberación inmediata
FI4084778T3 (fi) Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
ES2320847T3 (es) Formulaciones mejoradas de lamotrigina
CN108135833B (zh) 包含通过水电动力得到的纤维的药物组合物,该组合物具有在应用部位上改善的停留时间
JP2024019526A (ja) 脳癌の治療
RU2014119283A (ru) Твердая дисперсия
CN108201536A (zh) 一种奥拉帕尼口服缓控释药物组合物及其用途
US20170333404A1 (en) Improved formulations of vemurafenib and methods of making the same
CA3034875C (en) Combination therapies for the treatment of hepatocellular carcinoma
JP2017518985A (ja) アリサルタン・イソプロキシル固体分散体及び医薬組成物
JP2022534118A5 (cg-RX-API-DMAC7.html)
CN104338147B (zh) 一种用于缓控释给药的软膏组合基质
JP2023175825A (ja) 肝細胞癌の治療のための併用療法
EP2701689B1 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
JP7372740B2 (ja) 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
CN1414847A (zh) 含吡喹酮的缓释抗蠕虫组合物
WO2022166778A1 (zh) 一种衣壳蛋白抑制剂的药物组合物及其制备方法
CN1564691A (zh) 一种止痉挛剂的间隔药物释出系统
JP2024512069A5 (cg-RX-API-DMAC7.html)
US20250255822A1 (en) Triptolide formulations
CN106038566B (zh) 一种用于胃癌治疗的药物组合物及其应用
CN100441201C (zh) 含积雪草水溶性有效组分的中药缓释制剂及其制备方法
CN1539496A (zh) 治疗皮肤损伤的外用药物组合物